Biomea Fusion Inc. (BMEA), a clinical-stage biopharmaceutical company, is set to announce two data updates for its lead drug candidate Icovamenib this quarter.
Icovamenib is an oral, potent, and selective covalent inhibitor of menin, a key transcriptional regulator known to play a direct role in regulating the growth of beta cells in the pancreas as well as in oncogenic signaling in multiple cancers.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com